Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flunitrazepam: acute benefit-risk assessment in general practice.

C Hallett, B C Dean

    The Journal of International Medical Research
    |January 1, 1983
    PubMed
    Summary

    This study presents a practical method for evaluating a new drug

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Expert-Level Detection of Epilepsy Markers in EEG on Short and Long Timescales.

    NEJM AI·2025
    Same author

    Letter to the Editor: Announcement of a Call for Proposals for biomedical waveform coding.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2024
    Same author

    A computational framework for finding parameter sets associated with chaotic dynamics.

    In silico biology·2021
    Same author

    Time-intensive behavioural activation for depression: A multiple baseline study.

    Journal of behavior therapy and experimental psychiatry·2019
    Same author

    Understanding the phenomenological approach to research.

    Nurse researcher·2016
    Same author

    Inter-rater agreement on identification of electrographic seizures and periodic discharges in ICU EEG recordings.

    Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2014

    Area of Science:

    • Pharmacology
    • Clinical Trials
    • Drug Safety

    Background:

    • Assessing the benefit-risk ratio of new medications is crucial before market release.
    • Flunitrazepam is a sedative-hypnotic drug used for insomnia.

    Purpose of the Study:

    • To describe a practical methodology for assessing the pre-marketing benefit-risk ratio of a new drug.
    • To evaluate the benefit-risk profile of flunitrazepam.

    Main Methods:

    • A cohort of 2,435 patients received flunitrazepam at doses of 0.5 mg, 1.0 mg, or 2 mg nocte.
    • Effectiveness and acute risks were systematically assessed.

    Main Results:

    • Flunitrazepam demonstrated effectiveness in 78% of patients.
    • The acute risk associated with flunitrazepam was found to be predictable and low.
    • Risk levels were consistent across different ages and dosages.

    Conclusions:

    • The described methodology provides a practical approach to pre-marketing drug assessment.
    • The acute benefit-risk ratio for flunitrazepam, within its prescribed class and indication, is deemed acceptable.

    Related Experiment Videos